Apixaban plus P2Y12 inhibitor ‘likely best’ for AF after cardiac events
Antithrombotic regimen can be safely used 'across the spectrum of risks', researchers say
Apixaban plus a P2Y12 inhibitor without aspirin is a superior antithrombotic therapy in patients with AF after acute coronary syndromes or percutaneous coronary intervention, researchers say.
Their post-hoc analysis of the large, open-label AUGUSTUS trial indicates that this regimen was beneficial in this cohort, regardless of baseline risk of bleeding or stroke.
Drawing upon data from 4600 adults (mean age 71) with AF, the US clinicians assessed the efficacy and safety of antiplatelet and anticoagulant combinations according to individual bleed and stroke risk scores.
Participants had either had an acute coronary syndrome (ACS) or had undergone percutaneous coronary intervention (PCI).
